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Abstract
Death receptor 5 (DR5) and caspase-8 are major components in the extrinsic apoptotic pathway. The alterations of the
expression of these proteins during the metastasis of head and neck squamous cell carcinoma (HNSCC) and their prognostic
impact have not been reported. The present study analyzes the expression of DR5 and caspase-8 by immunohistochemistry
(IHC) in primary and metastatic HNSCCs and their impact on patient survival. Tumor samples in this study included 100
primary HNSCC with no evidence of metastasis, 100 primary HNSCC with lymph node metastasis (LNM) and 100 matching
LNM. IHC analysis revealed a significant loss or downregulation of DR5 expression in primary tumors with metastasis and
their matching LNM compared to primary tumors with no evidence of metastasis. A similar trend was observed in caspase-8
expression although it was not statistically significant. Downregulation of caspase-8 and DR5 expression was significantly
correlated with poorly differentiated tumors compared to moderately and well differentiated tumors. Univariate analysis
indicates that, in HNSCC with no metastasis, higher expression of caspase-8 significantly correlated with better disease-free
survival and overall survival. However, in HNSCC with LNM, higher caspase-8 expression significantly correlated with poorer
disease-free survival and overall survival. Similar results were also generated when we combined both DR5 and caspase-8.
Taken together, we suggest that both DR5 and caspase-8 are involved in regulation of HNSCC metastasis. Our findings
warrant further investigation on the dual role of caspase-8 in cancer development.
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Introduction
More than 35,000 people in the United States and more than
500,000 worldwide are estimated to be diagnosed with head and
neck squamous cell carcinoma (HNSCC) annually [1,2]. The
presence of metastasis in patients with head and neck cancer is
common and the 5-year survival rate for patients with lymph node
metastasis is approximately 25–50% [3]. Better treatments for
metastatic HNSCC are urgently needed. However, our under-
standing of the factors that regulate metastasis in this disease is
limited.
Death receptor 5 (DR5) is one of the cell surface receptors that
when activated by its ligand, tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), induces the activation of the
extrinsic apoptotic pathway in humans [4]. DR5 has been shown
to be overexpressed in several types of cancer including colon, lung
and cervical cancer [5–9]. Increased DR5 expression was also
associated with reduced survival in non-small cell lung cancer
[7,9]. A recent mouse study has shown that deficiency of TRAIL
receptor in mice (only one receptor for TRAIL in mouse) enhances
lymph node metastasis (LNM) without affecting primary tumor
development [10], suggesting that TRAIL receptor or TRAIL-
TRAIL receptor interaction may be critical for regulation of
tumor metastasis. Agonistic antibodies targeting DR5 are
currently in clinical trials for treatment of various types of cancer
[11]. Currently, the role of DR5 in metastasis is unknown and the
expression of DR5 in primary and metastatic HNSCC has not
been examined.
Caspase-8 is the first caspase activated during death receptor-
initiated apoptosis [12]. There is evidence of increased expression of
caspase-8 in several types of cancer including colorectal and rectal,
gastric, pancreatic, and breast cancers [13,14–17]. Besides, it has
been also shown that caspase-8 expression is lost or inactivated in
certain types of cancer such as small cell lung cancer, neuroblas-
toma, gastric carcinoma and hepatocellular carcinoma [18–25].
Loss of caspase-8 has been associated with metastasis in neuroblas-
toma [26]. However, it has also been recently shown that caspase-8
is associated with cell migration and can promote metastasis in
apoptotic resistant cells [27,28]. Moreover, a loss of caspase-8 was
reported to be associated with unfavorable survival in childhood
medulloblastoma [29]. Caspase-8 expression in HNSCC, particu-
larly in metastatic HNSCC, has not been documented.
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12178Thus, this study was particularly interested in comparing the
expression patterns of DR5 and caspase-8 between primary
HNSCC without LNM and HNSCC with LNM. To this end, we
performed immunohistochemistry (IHC) to detect DR5 and
caspase-8 on three groups of tumor samples from patients with
either primary tumors with no evidence of LNM, primary tumors
with LNM and the matching LNM.
Materials and Methods
Tissue Specimens
This study was approved by the Institutional Review Board at
Emory University. Tissues were obtained from surgical specimens
of patients who had HNSCC diagnosed at Emory University
Hospital and whose initial treatment was surgery without receiving
prior treatment with radiation and/or chemotherapy. The
selection criteria of the available formalin-fixed and paraffin-
embedded tissue blocks included 2 patient groups: primary
HNSCC with LNM (Tu
+met), their paired LNM, and primary
HNSCC with negative LNM (Tu
2met). In the Tu
2met group, if
any patient developed metastases within 2 years of the initial
procedure, they were excluded from the study. Each category has
100 samples. The clinical information on the samples was
obtained from the surgical pathology files in the Department of
Pathology at Emory University according to the regulations of the
Health Insurance Portability and Accountability Act (HIPAA).
This was a retrospective study which used tissue samples from
surgical specimens dated prior to April 14, 2003 and therefore was
exempt for consent requirement from HIPPA regulations. The
clinicopathologic parameters for the 2 study groups, including age,
gender, smoking history, tumor location, and histologic grade are
listed in Table 1.
IHC
Formalin-fixed, paraffin-embedded tissue sections were used for
IHC. Tissues were deparaffinized, hydrated through graded
ethanols, and microwaved in 100 mmol/L sodium citrate for 5
minutes at high power and 10 minutes at low power for antigen
retrieval. Detection of caspase-8 and DR5 was performed
following the DAKO Visualization System instructions using
3,3-diaminobenzidine tetrahydrochloride substrate to visualize the
proteins (DAKO, Carpinteria, CA). The slides were incubated
with caspase-8 polyclonal antibody (1:100 dilution) (NeoMarkers,
Fremont, CA) or DR5 polyclonal antibody (1:250 dilution)
(ProSci, Inc., Poway, CA) overnight at 4uC.
Both percentage of positive staining in tumor cells and intensity
of staining were scored. The intensity of IHC staining was
measured by using a numerical scale (0=no expression, 1=weak
expression, 2=moderate expression, 3=strong expression). The
staining data were finally quantified as the weighted index (WI)
(WI = % positive stain in tumor 6intensity score) as previously
described [30,31]. The WI was determined by 2 individuals, and
the final values were the average of the two readings.
Statistical Analysis
Median differences of the WIs for Caspase-8 and DR5 among
different groups were assessed with Mann-Whitney-Wilcoxon rank
test. Median differences between paired samples Tu
+met and LNM
were analyzed with Wilcoxon signed rank test. Correlations of the
WIs and the clinical characteristics for caspase-8 and DR5 were
performed in all the patients and within each group and in the
combined sample (Tu
2met and Tu
+met) after adjusting with
patients’ metastatic status. Logistic regression model was applied
to assess association between the WIs and binary variables (gender
and smoking status). Kruskal-Wallis tests were performed for
categorical variables with more than two categories (tumor site,
tumor size, node status and differentiation status). The Cox
proportional hazards model was used for univariate and
multivariable survival analysis for continuous Caspase-8 and
DR5. The proportional hazards assumption was assessed using
Schoenfeld residuals. Caspase-8 and DR5 were also dichotomized
as low and high based on the observed mean value. The log-rank
test was used to test whether Kaplan-Meier survival estimators
with different Caspase-8 or DR5 levels are statistically different.
Multivariable analyses were performed with those clinical
variables shown to be statistically significant in the univariate
analyses. All data processing and statistical analyses were
conducted using SAS version 9 (SAS Institute, Cary, NC).
Results
Detection of DR5 Expression in HNSCC
IHC analysis of DR5 was performed on 100 samples in each
group. A total of 94 samples in Tu
2met, 92 samples in Tu
+met and
85 samples in LNM group had acceptable tumor tissues for
evaluation. All samples in Tu
2met and Tu
+met were positive for
DR5 staining, whereas LNM tissues were 96% (82/85) positive for
DR5 staining. Figure 1 shows examples of DR5 staining in
different groups. DR5 was expressed primarily in the cytoplasm of
tumor cells. Some tumor stromal cells including fibroblasts and
immune cells were also positive for DR5. DR5 expression was
often decreased or lost in Tu
+met and corresponding LNM
Table 1. Clinic-pathologic features of the non-metastatic and
metastatic patient groups.
Clinical Parameters Non-metastatic Group Metastatic Group
Average age (years) 62.5 60.4
Gender
Men 62 68
Women 41 33
Smokers 81* 91**
Tumor location
Oral cavity 62 40
Oropharynx 7 33
Larynx 34 28
Tumor classification
T1 42 24
T2 31 38
T3 14 17
T4 15 22
Lymph node status
N1 - 19
N2 - 74
N3 - 8
Histologic grade
WD 30 3
MD 60 75
PD 11 23
*Six patients with unknown smoking status.
**Four patients with unknown smoking status.
doi:10.1371/journal.pone.0012178.t001
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statistically significant difference between DR5 expression in
Tu
2met and in Tu
+met and their matching LNM samples
(Figure 2A). Specifically, primary tumors without LNM (Tu
2met)
had significantly higher DR5 expression compared to both the
primary tumors with LNM (Tu
+met) and to LNM.
Detection of Caspase-8 Expression in HNSCC
IHC analysis of caspase-8 was also conducted in 100 samples in
each group. Among these samples, 96 Tu
2met,9 1T u
+met and 86
LNM samples could be evaluated. Some examples of caspase-8
staining were presented in Fig. 1. Similar to DR5 staining,
caspase-8 staining was also primarily cytoplasmic. Some tumor
stromal cells including fibroblasts and immune cells were positive
for caspase-8. Tumors in Tu
2met group exhibited a trend towards
a higher WI of caspase-8 than those in Tu
+met and LNM groups;
however, this result was not statistically significant (Fig. 2B).
DR5 Expression and its Correlation with Clinical
Parameters
We further analyzed the correlation between DR5 expression
and multiple clinical variables including gender, age at diagnosis,
smoking status, tumor site, tumor size, tumor stage, histologic
grade, node status, overall survival and disease free survival.
1) DR5 and tumor site. Univariate analysis showed that there
was a significant difference in the location of the site of the
tumor, characterized as oropharynx, larynx and oral cavity
and the WI of DR5. Specifically, tumors in Tu
+met group
arising in the oral cavity had significantly higher DR5
expression than tumors from this group that arose in the
oropharynx or larynx (P=0.0196).
2) DR5 and histologic grade. The histologic grade of the tumor
samples were characterized as well differentiated (WD),
moderately differentiated (MD) and poorly differentiated
(PD). By univariate analysis, there was a significant
correlation between histologic grade and DR5 expression.
Primary tumors in Tu
+met and their matching LNM
characterized as PD showed a significantly lower WI
compared to MD and WD tumors in these groups
(Figure 3A). Furthermore, multivariable analysis showed
that in Tu
+met group, the PD tumors showed a significantly
lower WI compared to tumors that were characterized as
MD or WD (P=0.0207). When combining all the patient
tumor samples, univariate and multivariable analysis showed
that histologic tumor grade was significantly correlated with
DR5 expression. Specifically those tumors identified as PD
have a lower DR5 WI compared to tumors identified as MD
and WD. WD tumors have a higher WI compared to MD
tumors. This result is consistent with analysis of the DR5 WI
and histologic grade when comparing each group of tumors
(Tu
+met, LNM, and Tu
2met) where we saw a decrease in
DR5 expression as the tumors became less differentiated.
3) DR5 and smoking status. Smoking status and DR5
expression was found to be significantly correlated when
combining all tumor samples. By univariate and multivar-
iable analysis, a lower DR5 WI was significantly associated
with smokers compared to non-smokers when both groups
of tumor samples were combined (i.e., Tu
2Met and Tu
+Met)
(P,0.05).
4) DR5 and patient survival. We analyzed whether DR5
expression has any effect on patient survival. Neither
univariate nor multivariable Cox proportional hazards
model revealed significant association between DR5 expres-
sion and patient survivals in either Tu
2met or Tu
+met group
(P.0.05). However, when DR5 expression was dichoto-
mized into low or high in terms of the observed mean value,
higher DR5 expression was significantly associated with
poorer disease-free survival (P=0.0458) in Tu
+met group
(Fig. 4B).
Figure 1. Representative IHC staining of DR5 and caspase-8 in different groups of HNSCC (2006).
doi:10.1371/journal.pone.0012178.g001
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Parameters
Similar to DR5, an analysis of the correlation between caspase-
8 expression and the clinical parameters including gender, age at
diagnosis, smoking status, tumor site, tumor size, tumor stage,
nodal status, histologic grade, overall survival and disease-free
survival was performed.
1) Caspase-8 and tumor site. Univariate analysis showed that there
was a significant difference in tumor location and the WI of
caspase-8. Tumors in Tu
+met group arising in the oral cavity and
their matching LNM had significantly higher caspase-8 expres-
sion than tumors that arose in the oropharynx or larynx (P,0.05).
2) Caspase-8 and histologic grade. By multivariable analysis, we
found that caspase-8 expression was significantly reduced in
PD primary tumors with metastasis (Tu
+met) compared to the
MD and WD tumors in this group (P,0.05). There were only
three tumors characterized as WD in this group, so the WD
and MD tumors were combined and their WI compared to
the PD tumors. By univariate analysis, the PD tumors in the
matching LNM had significantly less caspase-8 expression as
measured by the WI compared to the combined MD and
WD tumors in this group (Fig. 3B).
3) Caspase-8 and patient survival. We examined the impact of
caspase-8 on patient survival and found that caspase-8
expression correlated significantly with disease-free survival
and overall survival. Specifically, Cox proportional hazards
model showed that in tumors with no metastasis (Tu
2met),
higher expression of caspase-8 was associated with better
overall survival (P=0.0053, HR=0.994), while in tumors with
LNM (Tu
+met), higher caspase-8 expression was associated
with poorer overall survival (P=0.0347, HR=1.003). The
Log-rank test with dichotomized caspase-8 level showed the
sameeffectswithoverallsurvival(Figs.5Aand 5B).Inaddition,
the same effect was also observed with disease free survival
(P=0.0154 and 0.0044 in Tu
2met and Tu
2met group
Figure 2. Comparison of DR5 (A) and caspase-8 (B) expression among different groups of HNSCC. Difference between two groups was
evaluated with paired t test.
doi:10.1371/journal.pone.0012178.g002
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adjusting for age, tumor stage, gender, histologic grade,
smoking, chemo and/or radiation therapy, and tumor site
showed that high caspase-8 (greater than mean) in the Tu
2met
group was also significantly associated with better overall
survival (P=0.0026, HR=0.255; see supplemental Table S1).
Fig. 3. Comparison of DR5 (A) and caspase-8 (B) between poorly differentiated (PD) and well differentiated (WD)/moderate
differentiated (MD) HNSCC. Pictures are representative IHC staining of DR5 and caspase-8 (200X). Difference between two groups was evaluated
with paired t test.
doi:10.1371/journal.pone.0012178.g003
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Survival
Since both DR5 and caspase-8 are critical components in the
extrinsic apoptotic pathway, we further analyzed the impact of DR5
and caspase-8 combination on HNSCC patient survival. The Log-
rank test showed that the impact of the combined DR5 and caspase-8
on patient survival was identical to that of caspase-8 on patient
survival. Specifically, in HNSCC with no LNM (Tu
2met), patients
withhighlevelsofbothDR5andcaspase-8hadbetteroverallsurvival
and disease-free survival relative to patients with low levels of both
DR5andcaspase-8(P,0.0001andP=0.0124,respectively)(Fig.6A).
In contrast, in HNSCC with LNM (Tu
+met), patients with higher
levels of both DR5 and caspase-8 had worse overall survival and
disease-free survival relative to patients with low levels of both DR5
and caspase-8 (P=0.0270andP=0.0065, respectively) (Fig. 6B).
Discussion
The death receptor-mediated extrinsic apoptotic pathway plays
an essential role in host immunosurveillance against tumor
development, particularly metastasis [32–34]. In a genetic study,
knockout of TRAIL receptor in mice does not affect primary
tumor development, but enhances LNM [10], suggesting that
TRAIL receptor is important for suppressing tumor metastasis. In
human melanoma samples, a reduced DR5 expression was
reported to be associated with metastatic lesions [35]. In
agreement, the current study revealed a significant downregulation
of DR5 expression in primary tumors with LNM (Tu
+met) and
their matching LNM compared to primary tumors with no
metastasis (Tu
2met). Moreover, DR5 expression was significantly
reduced in PD tumors compared to MD and WD tumors.
Therefore, our data on DR5 from human HNSCC samples
supports an inhibitory role of DR5 in regulation of metastasis. The
mechanism of DR5 in regulation of metastasis is not known.
However, DR5 is involved in mediating anoikis, a form of
apoptosis triggered by loss of attachment of cells from the
extracellular matrix [36,37]. Therefore, it is possible that the loss
of DR5 we see in our metastatic HNSCC has contributed to the
inhibition of anoikis, therefore allowing the tumor cells to escape
apoptosis and migrate after detachment. It has been shown that in
non-small cell lung carcinoma tissues, increased expression of DR5
correlates with PD tumors. Moreover, high DR5 expression is
significantly associated with reduced overall survival [9]. However,
our data clearly show that reduced DR5 expression correlates
significantly with PD HNSCC. Furthermore, we did not find
significant association between DR5 expression and overall
Figure 4. Impact of DR5 expression on disease-free survival and overall survival in HNSCC patients without LNM (Tu
2met)( A) and in
HNSCC patients with LNM (Tu
+met)( B). Kaplan-Meier plots were generated according to high (greater than the mean value) and low (less than or
equal to the mean value) levels of DR5.
doi:10.1371/journal.pone.0012178.g004
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2met group. In Tu
+met group,
we found that the levels of DR5 were not associated with overall
survival. However, higher DR5 was significantly associated with a
worse disease-free survival. Despite the potential role of DR5 in
negative regulation of metastasis as discussed above, our study did
not show a survival advantage for Tu
+met HNSCC with high
expression of DR5. In fact, one study has shown that TRAIL
enhances the invasion of apoptosis-resistant pancreatic ductal
adenocarcinoma cells in vitro and increases distant metastasis (e.g.,
liver) of pancreatic tumors in vivo [38], suggesting that activation of
the DR5 signaling may facilitate metastasis under certain
conditions. Moreover, the major mediator of DR5, caspase-8,
has non-apoptotic functions that promote cell motility and
migration as discussed below. Thus, whether DR5, like caspase-
8, may also exert non-apoptotic functions, particularly in apoptotic
resistant cells (see discussion below), should be further investigated.
We noted that DR5 staining in our study was primarily in the
cytoplasm. However DR5 is known to be functional in inducing
apoptosis as a membrane-bound protein. Given that DR5
expression levels do impact patient prognosis as demonstrated in
this study, our data suggest that it may be interesting to study
whether membrane-bound and cytoplasmic DR5 proteins exert
distinct functions (e.g., apoptotic vs. non-apoptotic) under different
conditions.
It has been shown that cigarette smoke impairs tumor immune
surveillance and promotes invasion of cancer cells including oral
carcinoma cells and tumor metastasis in experimental systems [39–
43]. In this study, we found after examining all patient samples
together that a lower DR5 expression in HNSCC was significantly
associated with smokers compared to non-smokers. Thus, it would
be interesting to determine if tobacco carcinogens can downreg-
ulate DR5 expression and possibly add to the effect of tumor cells
escaping apoptosis or contributing to metastasis.
In addition to DR5, DR4 is another TRAIL receptor that can
initiate death signaling upon TRAIL binding or overexpression
[4]. Depending on tumor types, expression of DR4 has variable
impact on prognosis. For example, high DR4 expression has been
shown to be associated with worse disease-free survival, worse
overall survival and shorter time to recurrence in colon cancer [6],
whereas DR4 expression did not impact patient survival in lung,
cervical and ovarian cancers [7,44,45]. Moreover, in breast
cancer, DR4, in contrast to DR5, has been shown to be more
strongly expressed in better differentiated tumors, and correlated
positively with surrogate markers of a better prognosis (hormone
Fig. 5. Impact of caspase-8 expression on disease-free survival and overall survival in HNSCC patients without LNM (Tu
2met)( A) and
in HNSCC patients with LNM (Tu
+met)( B). Kaplan-Meier plots were generated according to high (greater than the mean value) and low (less than
or equal to the mean value) levels of caspase-8.
doi:10.1371/journal.pone.0012178.g005
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the expression of Her2/neu and the proliferation marker Ki67
[46]. In our study, we did not stain DR4 expression in our cohort
of HNSCC tissues, largely due to antibody issues. Nonetheless, it
will be interesting to study DR4 expression in HNSCC and its
association with LNM and prognosis in the future.
The major function of caspase-8 is to mediate apoptosis induced
by death receptors including DR5. It has been recently suggested
that caspase-8 can play dual roles: one as an inducer of apoptosis
and one as a promoter in metastasis [47]. Caspase-8 facilitates cell
death initiated from the death receptor pathway after a death
ligand (e.g., TRAIL) binds a death receptor (e.g., DR5) [48]. In
addition, caspase-8 can also promote cell migration [27,49–51]. It
has been suggested that caspase-8 can contribute to cell motility
and adhesion by regulating calpain activity which controls cell
migration including rac activation and lamellipodial assembly
[50]. As well, the phosphorylation of procaspase-8 on tyrosine 380
and its interaction with the p85 alpha subunit of phosphatidyli-
nositol 3-kinase was required to restore cell motility and adhesion
in caspase-8 null cells [49]. However, there is evidence that a loss
of caspase-8 is associated with increased metastasis. In neuroblas-
toma, a loss of caspase-8 prevented apoptosis by integrin-mediated
cell death and therefore promoted metastasis [26]. In our study,
caspase-8 expression trended towards a downregulation of
expression in the metastatic group of patients, but this result was
not statistically significant. Thus, it is unclear if the downregulation
of caspase-8 that we observed in invasive HNSCC was playing a
significant role in metastasis. It is possible that in primary tumors
caspase-8 predominantly contributes to apoptosis and therefore
can prevent metastasis, but in those tumor cells that escape
apoptosis (i.e., are resistant to apoptosis), caspase-8 may be
contributing to migration and metastasis. In our study, we found
that in primary tumors with no LNM (i.e., Tu
2met) higher
expression of caspase-8 correlated with better disease-free survival
and overall survival, however, in tumors with LNM (i.e., Tu
+met)
higher caspase-8 expression significantly correlated with worse
disease-free survival and overall survival. Similar results were also
generated when we analyzed the impact of caspase-8 and DR5
combination.Higher levels of both caspase-8 and DR5 in HNSCC
with no LNM (Tu
2met) was significantly associated with better
disease-free survival and overall survival, but was significantly
correlated with poorer disease-free survival and overall survival in
Figure 6. Impact of caspase-8 and DR5 combination on disease-free survival and overall survival in HNSCC patients without LNM
(Tu
2met)( A) and in HNSCC patients with LNM (Tu
+met)( B). Kaplan-Meier plots were generated according to high (greater than the mean value)
and low (less than or equal to the mean value) levels of DR5 and caspase-8.
doi:10.1371/journal.pone.0012178.g006
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+met). Thus, it is plausible to speculate that
caspase-8 (as well as DR5) in primary HNSCC without LNM
(Tu
2met) may be predominantly associated with its pro-apoptotic
function and thus higher caspase-8 or caspase-8 plus DR5 provides
protective advantage against cancer and correlates with better
survival.Whereas in HNSCC with LNM (Tu
+met) which are
resistant to apoptosis, caspase-8 and even DR5 may primarily
exert their non-apoptotic function, i.e., activation of PI3K and
promotion of migration, and thus higher caspase-8 expression
negatively impacts patient survival. A limitation of the current
study is the existence of potential bias due to usage of selected
patient populations and retrospective design although no tumor
pretreatment was the major criteria for tumor selection.
Nonetheless, our interesting findings warrant further study to
demonstrate the precise role of caspase-8 as well as DR5/caspase-
8 pathway in regulation of HNSCC metastasis.
In summary, our IHC analysis of caspase-8 and DR5 in
HNSCC suggest that a loss or downregulation of DR5 expression
and possibly caspase-8 expression may be associated with more
metastatic tumors and a loss of differentiation. The overall high
expression of DR5 and caspase-8 in both primary and metastatic
HNSCC suggests that DR5 or caspase-8 may be a good target for
therapy of HNSCC. Various agonistic DR5 antibodies such as
Conatumumab (AMG655), CS-1008 and Lexatumumab have
been currently tested in cancer clinical trials either as a single
agent or in combination with other therapeutic agents. Early
clinical trials of these agents have established the safety of the
approach and showed proof-of-concept antitumor activity [52].
Thus, our current findings warrant further study on targeting DR5
for potential treatment of HNSCC.
Supporting Information
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Found at: doi:10.1371/journal.pone.0012178.s001 (0.04 MB
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